INCB018424 in Patients With Advanced Hematologic Malignancies

Phase 2 Completed 51 enrolled M.D. Anderson Cancer Center Incyte Corporation · collab

NaSingle-groupOpen-labelTreatment

Summary

The goal of this clinical research study is to learn if ruxolitinib can help to control advanced hematological malignancies. The safety of this drug will also be studied.

Timeline

Start: 2008-05-12
Primary completion: 2017-03-23
Completion: 2017-03-23

Publications

Eghtedar A, Verstovsek S, Estrov Z, Burger J, Cortes J, Bivins C, Faderl S, Ferrajoli A, Borthakur G, George S, Scherle PA, Newton RC, Kantarjian HM, Ravandi F. Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia. Blood. 2012 May 17;119(20):4614-8. doi: 10.1182/blood-2011-12-400051. Epub 2012 Mar 15.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ruxolitinib	Small molecule	25 mg	Oral
Subject	Ruxolitinib	Small molecule	50 mg	Oral

INCB018424 in Patients With Advanced Hematologic Malignancies

Summary

Timeline

Publications

Drugs

Indications